Pharma Sector

The pharmaceutical stock was offered on public markets in May of last year, at a 20% premium to its issue price of ₹1,080.

Against its annual contracted value of USD50m supplies for Librela, Syngene has supplied USD94m worth of Librela to Zoetis over the past 13 months, which likely implies that Librela supplies to Zoetis will continue to taper off in CY24 and will present a tough base for Syngene going ahead. Syngene shipped just USD2m worth of Librela in Feb’24 vs USD21/13m in Dec’23/Jan’24 respectively.

The complaint alleges Dr Reddy's "improperly restrained competition" and maintained a monopoly for the cancer drug Revlimid.

Under the terms of the agreement, the product may be introduced in the US in February 2025 after receiving FDA approval.

The price band for Mukka Proteins IPO is between ₹26 to ₹28 per equity share, with a lot size of 535 shares and multiples thereafter

According to a press release from Suven Pharmaceuticals, the entire deal is anticipated to be completed within the next 12 to 15 months

Aurobindo Pharma markets its products in over 125 countries, with key partners like AstraZeneca and Pfizer

The public offer exclusively comprises a fresh issue of up to 8 crore equity shares, with no offer-for-sale (OFS) component.

The US private equity group is trying to employ financial consultants.

During the IPO, which concluded on February 26th, the price band was set between ₹177 and ₹186 per share.